Analyst Ratings For CytRx Corporation (NASDAQ:CYTR)
Today, HC Wainwright set its price target on CytRx Corporation (NASDAQ:CYTR) to $5.00 per share.
There are 1 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.
The current consensus rating on CytRx Corporation (NASDAQ:CYTR) is Buy with a consensus target price of $5.00 per share, a potential 316.67% upside.
Some recent analyst ratings include
- 3/21/2017-Aegis Reiterated Rating of Buy.
Recent Insider Trading Activity For CytRx Corporation (NASDAQ:CYTR)
CytRx Corporation (NASDAQ:CYTR) has insider ownership of 6.60% and institutional ownership of 4.67%.
- On 12/3/2013 Scott Bradford Patterson, major shareholder, bought 284,979 with an average share price of $2.44 per share and the total transaction amounting to $695,348.76.
- On 11/7/2013 Scott Bradford Patterson, Major Shareholder, bought 50,000 with an average share price of $2.06 per share and the total transaction amounting to $103,000.00.
- On 4/1/2013 Scott Bradford Patterson, Major Shareholder, bought 4,083 with an average share price of $2.70 per share and the total transaction amounting to $11,024.10.
- On 3/20/2013 Scott Bradford Patterson, Major Shareholder, bought 3,980 with an average share price of $2.61 per share and the total transaction amounting to $10,387.80.
- On 3/13/2013 Scott Bradford Patterson, Major Shareholder, bought 55,360 with an average share price of $2.67 per share and the total transaction amounting to $147,811.20.
- On 10/22/2012 Scott Bradford Patterson, Major Shareholder, bought 180,000 with an average share price of $2.51 per share and the total transaction amounting to $451,800.00.
- On 10/18/2012 Scott Bradford Patterson, Major Shareholder, bought 1,200,000 with an average share price of $2.50 per share and the total transaction amounting to $3,000,000.00.
About CytRx Corporation (NASDAQ:CYTR)
CytRx Corporation, a biopharmaceutical company, engages in the research and clinical development of novel anti-cancer drug candidates that employ linker technologies to enhance the accumulation and release of drug at the tumor. The company is developing its pipeline of oncology candidates at its laboratory facilities in Freiburg, Germany, through its LADR (linker activated drug release) technology platform, a discovery engine designed to leverage its expertise in albumin biology and linker technology for the development of anti-cancer therapies. Its lead drug candidate is Aldoxorubicin, an improved version of anti-cancer drug doxorubicin out-licensed to NantCell, Inc. Aldoxorubicin is in late-stage clinical development for the treatment of relapsed soft tissue sarcoma, as well as evaluating in various other cancer indications with unmet clinical need, including small-cell lung cancer. CytRx Corporation was founded in 1985 and is headquartered in Los Angeles, California.
Recent Trading Activity for CytRx Corporation (NASDAQ:CYTR)
Shares of CytRx Corporation closed the previous trading session at 1,20 −0,020 1,64 % with 1.2 shares trading hands.
